X4 Pharmaceuticals Q3 revenue rises on XOLREMDI sales

By Reuters News


Overview

  • US rare hematology drug developer's Q3 revenue rose yr/yr, driven by higher XOLREMDI sales

  • Net loss for Q3 narrowed from prior year

  • Company secured $150 mln loan facility, cash runway expected into Q1 2029


Outlook

  • Company expects to complete 4WARD trial enrollment in Q4 2026; topline data due Q1 2028

  • First participant in 4STEPS Phase 2b trial expected to enroll in Q1 2027

  • Company says cash runway extends into Q1 2029


Result Drivers

  • LOWER R&D EXPENSES - Co said reduced headcount from 2025 restructuring led to lower R&D expenses

  • LOWER G&A EXPENSES - Co attributed decrease in G&A expenses to reduced legal and compensation costs, and lower sales and marketing spend


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Net Loss

$20.20 mln

Q3 Income from Operations

-$19.99 mln

Q3 Operating Expenses

$22.87 mln


Analyst Coverage

  • The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

  • Wall Street's median 12-month price target for X4 Pharmaceuticals, Inc. is $12.00, about 278.5% above its November 3 closing price of $3.17


Reuters Recommended Reads

  • Nov 3 - Ultragenyx Q3 revenue rises, net loss narrows

  • Nov 2 - Travere Q3 product sales nearly double on FILSPARI growth

  • Nov 3 - Zevra Therapeutics Q3 revenue rises 45% on MIPLYFFA sales


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk